{"entity":{"id":"rupert-bartsch","kind":"person","name":"Rupert Bartsch","aka":[],"tldr":"Vienna oncologist who led TUXEDO-1, the small trial that showed trastuzumab deruxtecan can shrink active brain metastases from HER2-positive breast cancer.","summary":"Rupert Bartsch is a medical oncologist at the Medical University of Vienna who focuses on brain metastases from breast cancer. He was first author of the 2022 Nature Medicine report of TUXEDO-1, a single-arm phase 2 trial in which trastuzumab deruxtecan produced intracranial responses in most patients with active brain metastases from HER2-positive breast cancer, evidence that the antibody-drug conjugate works in the brain.","asOf":"2026-09-18","links":[],"tags":["breast","brain-metastases","trialist"],"related":[],"cancers":["her2-positive-breast-brain-metastases","breast-her2-positive","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ccc-vienna"],"pathways":[],"terms":[],"trials":["tuxedo-1"],"people":[],"bottlenecks":[],"keyPapers":["paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Medical University of Vienna","institutionId":"ccc-vienna","specialisms":["Breast cancer brain metastases","HER2-positive breast cancer","Antibody-drug conjugates"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bartsch%5BAuthor%5D"}],"papers":[]},"route":"/people/rupert-bartsch/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"her2-positive-breast-brain-metastases","kind":"cancer","name":"HER2-positive breast cancer with brain metastases","route":"/cancers/her2-positive-breast-brain-metastases/"}],"institution":[{"id":"ccc-vienna","kind":"institution","name":"Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH","route":"/institutions/ccc-vienna/"}],"trial":[{"id":"tuxedo-1","kind":"trial","name":"TUXEDO-1","route":"/trials/tuxedo-1/"}],"paper":[{"id":"paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022","kind":"paper","name":"TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases","route":"/key-papers/paper-tuxedo-1-trastuzumab-deruxtecan-brain-metastases-nat-med-2022/"}]}}